Navigation Links
Versus Technology Announces Third Quarter Results
Date:8/28/2008

000

Changes in operating assets and liabilities:

Accounts receivable 473,000 890,000

Inventories (79,000) (184,000)

Prepaid expenses and other current assets (64,000) (85,000)

Accounts payable (53,000) (36,000)

Accrued expenses (39,000) (2,000)

Deferred revenues - customer advance

payments (104,000) (46,000)

Net cash (used in) provided by operating

activities (574,000) 140,000

Investing Activities

Additions to property and equipment (281,000) (33,000)

Financing Activities

Issuance of common stock 117,000 352,000

Net (Decrease) Increase in Cash and

Cash Equivalents (738,000) 459,000

Cash and Cash Equivalents, at the

beginning of the period 2,428,000 1,401,000

Cash and Cash Equivalents, at the end

of the period $1,690,000 $1,860,000

See accompanying report of management.


'/>"/>
SOURCE Versus Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Versus Technology Announces Fourth Quarter Results
2. Smart Home Cleaning: New Web Site Educates Consumers on Looking Clean Versus Being Clean
3. Occlutech Wins Confirmation of its Intellectual Property Position Versus AGA Medical Patent by AIPPI
4. Versus Technology Announces First Quarter Results
5. Birner Dental Management Services, Inc. Announces 10.0% Adjusted EBITDA Increase for 2007 Versus 2006
6. Versus Technology, Inc. Announces Collaboration with Cleveland Clinic to Create Clinical Patient Flow Model
7. Eat Well, Save Money: BJs Offers Everyday Low Prices on Top Quality Organic Groceries, Natural Foods Versus Supermarket Prices
8. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
9. Quantum light beams good for fast technology
10. New Smart Technology Makes Patient Data Collection Easier, More Efficient
11. Align Technology Executive to Present at Upcoming Financial Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...TON, Nov. 21 The Unive...d the beginning of a collaborative effort to eradi...ip for Breast Cancer Awareness and Research of the...irst Lady of the United States, and Vivian Fernand... Joining M. D. Anderson in the initiative are th...
(Date:11/21/2008)...MBIA, S.C., Nov. 21 U.S...ee for Quality Assurance (NCQA) ranked BlueChoice(...f America,s Best Health Plans(TM), published in U.... , The respected annual ranking ranks the nati...member satisfaction and NCQA accreditation scores....
(Date:11/21/2008)...y found 2 popular drugs do not cause genetic damag...ov. 21 (HealthDay News) -- Two popular medications...rder (ADHD) do not cause genetic damage linked to ...dy says. , The study, done by researchers at Du...itutes of Health, counters a previous one that rep...
(Date:11/21/2008)...YORK, Nov. 21 /PRNewswire/ -- For the second ye...ars , McCann Healthcare Worldwide,s agency networ...etwork at the 22nd annual international RX Club Sh...gency offices won a total of 59 RX Club Awards of ...inning McCann Healthcare Worldwide agencies includ...
Breaking Medicine News(10 mins):Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research Extends to Panama 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 2Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 3Health News:McCann Healthcare Worldwide Agencies Again Win Most Awards at RX Club Show 2008 4
...tors have a reputation to disagree with any other ...Scotland are recommending art classes to have a be... doctors has been appointed at the GP practice in ...tion is Susan Grant, a graduate of the Edinburgh S...
...s all wired at birth. Even the sex drive, research...ly therapy may not work to cure 'sex addicts'// , ... hold the clue, for people who are more driven tha... We owe this discovery to researchers from Hebrew ...
...sia has begun testing a vaccine to prevent bird fl...d. Russia has not had any human infections to date...d 1.1 million birds either through disease or thro...n 120 volunteers," said Vitaly Zverev, the head of...
...cer centres in Singapore and India plan to expand ...ity-state's leading cancer centre said Tuesday//. ...r Centre (NCC) and the Kerala-based Regional Cance...me credited with cutting the death rate from mouth...
Other Medicine News:
(Date:11/20/2008)...P LINE RESULTS OF FIRST PHASE III TRIAL SHOW SIGNI...PROVEMENT IN DAILY FUNCTION, IN, ... Calif., and BRUSSELS, Belgium, Nov. 20 /PRNewswir...q: JAZZ ) and UCB (Euronext Brussels: UCB),anno...from the first of two,Phase III pivotal clinical ...
(Date:11/20/2008)...Nov. 20 Duska Therapeuti...oday that it has submitted its,pivotal Phase 3 AT...ecial,Protocol Assessment (SPA) procedure with th... Subject to securing an agreement with the FDA, ...double-blind, placebo-controlled and randomized Ph...
(Date:11/20/2008)..., November 20 The Scandinavian-bas...nnounced results of studies on its,lead antimicro...ington, DC,the studies showed that the novel lyt...l effect, significantly better towards killing Sta...n marketed gold standard drugs. In,addition to th...
(Date:11/19/2008)...s report basic findings on critical enzyme,s regul...treat an array of disorders , , MEMPHIS, Te...s at St. Jude Children,s Research Hospital have ga...dy,s enzyme workhorses called calpains. , , ...function in many cellular processes, including the...
Breaking Medicine Technology:Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 2Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 3Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 4Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 5Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia 6Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3New research about chronic lung disease presented at CHEST 2008 27898 1New research about chronic lung disease presented at CHEST 2008 27898 2New research about chronic lung disease presented at CHEST 2008 27898 3New research about chronic lung disease presented at CHEST 2008 27898 4New research about chronic lung disease presented at CHEST 2008 27898 5New research about chronic lung disease presented at CHEST 2008 27898 6New research about chronic lung disease presented at CHEST 2008 27898 7CHEST 2008 3A Featured abstracts 27895 1CHEST 2008 3A Featured abstracts 27895 2CHEST 2008 3A Featured abstracts 27895 3CHEST 2008 3A Featured abstracts 27895 4CHEST 2008 3A Featured abstracts 27895 5CHEST 2008 3A Featured abstracts 27895 6CHEST 2008 3A Featured abstracts 27895 7CHEST 2008 3A Featured abstracts 27895 8CHEST 2008 3A Featured abstracts 27895 9CHEST 2008 3A Featured abstracts 27895 10CHEST 2008 3A Featured abstracts 27895 11CHEST 2008 3A Featured abstracts 27895 12CHEST 2008 3A Featured abstracts 27895 13CHEST 2008 3A Featured abstracts 27895 14CHEST 2008 3A Featured abstracts 27895 15CHEST 2008 3A Featured abstracts 27895 16CHEST 2008 3A Featured abstracts 27895 17CHEST 2008 3A Featured abstracts 27895 18Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing Tuskegee Effect When Recruiting Minorities for Research Studies 27894 1Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing Tuskegee Effect When Recruiting Minorities for Research Studies 27894 2Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing Tuskegee Effect When Recruiting Minorities for Research Studies 27894 3Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing Tuskegee Effect When Recruiting Minorities for Research Studies 27894 4Town Hall Meeting on Inequities in Clinical Trials Documents Ongoing Tuskegee Effect When Recruiting Minorities for Research Studies 27894 5AUL Action Releases Open Letter to Sen Obama 3A Why do you oppose parental notification laws that protect our children from sexual abuse 3F 27891 1
...tivity and Metabolic,Enzymes Show How Cells Respon..., a Key Player in the Daily Biochemical Routines t...PRNewswire/ -- Investigators at,St. Jude Children,...namic genetic and biochemical changes that make up...led Coenzyme A (CoA), a key,player in metabolism. ...
... - Pfizer said today that,results from two new ima...d the progression of atherosclerosis in patients w...terolemia (FH). The,trials, which were designed to...ional compound torcetrapib in combination with,Lip...ay at the,annual meeting of the American College o...
Other Medicine Technology:Study Shows Metabolic Strategy of Stressed Cell 2Study Shows Metabolic Strategy of Stressed Cell 3Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis 2Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis 3Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis 4Two New Imaging Studies Show Higher Dose Lipitor Stopped the,Progression of Atherosclerosis 5
...cardial permanent pacing leads with an extendable/...y size of only 4.8 F and a lead tip size of 7 F, t...table bipolar pacing lead available today. Availab...s, Physique leads are ideal for placement in the a...
Implantable medical grade silicone sleeve for adapting a 5 mm (01) connector to a 6 mm (02) connector.
...nciple has been applied to cardiac resynchronizati..., which consists of the Tupos LV/A+ and the five-p...y and the risk of complications. The ICD receives ...ngle lead. The atrial input stage of the Tupos LV/...
...nchronization therapy defibrillator provides ventr...ronization therapy. Features: Independently progra... (LV) pacing and sensing. Designed to reduce irreg... arrhythmias. Designed to maintain atrial-tracked ...
Medicine Products: